drugset / Trial / NCT01653158
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.
Timeline
- Start
- 2005-03
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Figitumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
Indications
No indication recorded.